Table 1 Overview of study designs considered in simulations
From: Preventing false discovery of heterogeneous treatment effect subgroups in randomized trials
Effect type | Study setting | |
|---|---|---|
N = 200 phase II oncology trial | N = 6000 phase III CVD trial | |
ATE > 0, no HTE subgroups | Simulation 1A | Simulation 2A |
ATE> 0, HTE subgroups exist | Simulation 1B | Simulation 2B |
ATE = 0, HTE subgroups exist | Simulation 2C | |